Home › Funds › Vestal Point Capital, LP › ABT

Vestal Point Capital, LP position in ABT

ABBOTT LABORATORIES · Health Care

Vestal Point Capital, LP reported holding 1,400,000 shares of ABT (ABBOTT LABORATORIES) in its Q2 2026 13F filing — a position valued at US$127.0M, representing 2.97% of its reported portfolio and ranking #10 among its reported holdings. Vestal Point Capital, LP has disclosed ABT holdings in 4 of the last 5 reported quarters, going back to Q2 2025.

Latest position (Q2 2026)1.40M sh
Reported value held$127.04M
Portfolio Weight2.97%
First reportedQ2 2025
Last changeNew
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Vestal Point Capital, LP's ABT position evolved

Vestal Point Capital, LP first disclosed a stake in ABT in Q2 2025 at 175,000 shares (US$23.8M). The position peaked in Q2 2026 at 1,400,000 shares, worth US$127.0M. Across 4 filings, Vestal Point Capital, LP increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 1,400,000 shares valued at US$127.0M. Notable position changes include a 43% increase in Q3 2025 (shares fell 6% over the following quarter), a 140% increase in Q4 2025 (shares fell 18% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q2 2025 175.00K $23.80M New
Q3 2025 250.00K $33.48M Add
Q4 2025 600.00K $75.17M Add
Q2 2026 1.40M $127.04M New

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ABT and 13F data

ABT (ABBOTT LABORATORIES) is a Health Care company. 20 other funds we track also report a position in ABT — the largest reported positions include Vanguard Group (US$22.00B), Charles Schwab Investment Management (US$5.41B), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (US$5.41B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ABT

All ABT fund holders →

FAQ

How long has Vestal Point Capital, LP held ABT?

Vestal Point Capital, LP has disclosed ABT holdings in 4 of the last 5 reported quarters, going back to Q2 2025.

What is Vestal Point Capital, LP's current position in ABT?

As of Q2 2026, Vestal Point Capital, LP holds 1.40M shares of ABT (ABBOTT LABORATORIES), valued at $127.04M, representing 2.97% of its reported portfolio and ranking #10.

Has Vestal Point Capital, LP been buying or selling ABT?

In the latest 13F filing (Q2 2026), Vestal Point Capital, LP newly opened its position in ABT. The position peaked in Q2 2026 at 1.40M shares.

Which other funds hold ABT?

Other major institutional holders of ABT include Vanguard Group, Charles Schwab Investment Management, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, among 20 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.